For the latest updates on Gilead’s ongoing response to COVID-19, please click here.

Investor Relations

Contact Us

KiteKonnect®

Newsroom

Recent Press Releases

November 04, 2021
Gilead and Kite Oncology Demonstrate Broad Leadership in Cell Therapy and Expanding Blood Cancer Pipeline
October 01, 2021
U.S. FDA Approves Kite’s Tecartus® as the First and Only Car T for Adults With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia

Recent Company Statements

February 9, 2021
Kite Announces U.S. FDA Clearance of Investigational New Drug Application for KITE-222, an Anti-CLL-1 CAR T-Cell Therapy Candidate for Acute Myeloid Leukemia

Explore More

Media Inquiries

Gilead Newsroom